BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33761869)

  • 1. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.
    Shadman Z; Farajnia S; Pazhang M; Tohidkia M; Rahbarnia L; Najavand S; Toraby S
    BMC Infect Dis; 2021 Mar; 21(1):300. PubMed ID: 33761869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human single-chain antibodies that neutralize Pseudomonas aeruginosa-exotoxin A-mediated cellular apoptosis.
    Santajit S; Seesuay W; Mahasongkram K; Sookrung N; Ampawong S; Reamtong O; Diraphat P; Chaicumpa W; Indrawattana N
    Sci Rep; 2019 Oct; 9(1):14928. PubMed ID: 31624289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
    Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
    Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
    Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
    Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunobiological properties of recombinant atoxic forms of the Pseudomonas aeruginosa exotoxin A].
    Isakov MA; Soldatenkova AS; Kaloshin AA; Mikhaĭlova NA
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):37-42. PubMed ID: 21598613
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Shadman Z; Ghasemali S; Farajnia S; Mortazavi M; Biabangard A; Khalili S; Rahbarnia L
    Infect Disord Drug Targets; 2023; 23(5):e290323215113. PubMed ID: 36999425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
    Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
    MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Production and properties evaluation of monoclonal antibodies against Pseudomonas aeruginosa exotoxin A].
    Soldatenkova AV; Iakovleva IV; Gavrilova NV; Mikhaĭlova NA; Sviridova VV
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):30-5. PubMed ID: 24738291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
    Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
    Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
    Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of protective properties of recombinant atoxic form of exotoxin A and recombinant outer membrane protein F of Pseudomonas aeruginosa].
    Mikhaĭlova NA; Vertiev IuV; Kaloshin AA; Isakov MA
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):39-44. PubMed ID: 20464999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterization of human monoclonal antibody recognizing the N-terminal residues of Pseudomonas aeruginosa exotoxin A.
    Ohtsuka H; Horigome K; Ochi H; Nishimoto T; Kozuki T; Kato M; Okuda T; Noguchi H
    Hybridoma; 1991 Apr; 10(2):297-307. PubMed ID: 1651902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
    Pier GB
    Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
    Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
    Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host translational inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an immune response in Caenorhabditis elegans.
    McEwan DL; Kirienko NV; Ausubel FM
    Cell Host Microbe; 2012 Apr; 11(4):364-74. PubMed ID: 22520464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
    Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
    J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
    Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
    Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.